246 related articles for article (PubMed ID: 33383047)
1. Immune-related IncRNA LINC00944 responds to variations in ADAR1 levels and it is associated with breast cancer prognosis.
de Santiago PR; Blanco A; Morales F; Marcelain K; Harismendy O; Sjöberg Herrera M; Armisén R
Life Sci; 2021 Mar; 268():118956. PubMed ID: 33383047
[TBL] [Abstract][Full Text] [Related]
2. ADAR1 expression is associated with tumour-infiltrating lymphocytes in triple-negative breast cancer.
Song IH; Kim YA; Heo SH; Park IA; Lee M; Bang WS; Park HS; Gong G; Lee HJ
Tumour Biol; 2017 Oct; 39(10):1010428317734816. PubMed ID: 29022489
[TBL] [Abstract][Full Text] [Related]
3. Identification of Five Immune-Related lncRNAs Predicting Survival and Tumor Microenvironment Characteristics in Breast Cancer.
Xiao R; Yang M; Tan Y; Ding R; Li D
Comput Math Methods Med; 2021; 2021():6676692. PubMed ID: 33727952
[TBL] [Abstract][Full Text] [Related]
4. ADAR1-mediated RNA-editing of 3'UTRs in breast cancer.
Sagredo EA; Blanco A; Sagredo AI; Pérez P; Sepúlveda-Hermosilla G; Morales F; Müller B; Verdugo R; Marcelain K; Harismendy O; Armisén R
Biol Res; 2018 Oct; 51(1):36. PubMed ID: 30290838
[TBL] [Abstract][Full Text] [Related]
5. Up-regulated lncRNA AFAP1-AS1 indicates a poor prognosis and promotes carcinogenesis of breast cancer.
Ma D; Chen C; Wu J; Wang H; Wu D
Breast Cancer; 2019 Jan; 26(1):74-83. PubMed ID: 29974352
[TBL] [Abstract][Full Text] [Related]
6. LncRNA MEG3 acts a biomarker and regulates cell functions by targeting ADAR1 in colorectal cancer.
Wang W; Xie Y; Chen F; Liu X; Zhong LL; Wang HQ; Li QC
World J Gastroenterol; 2019 Aug; 25(29):3972-3984. PubMed ID: 31413531
[TBL] [Abstract][Full Text] [Related]
7. lncRNA TCL6 correlates with immune cell infiltration and indicates worse survival in breast cancer.
Zhang Y; Li Z; Chen M; Chen H; Zhong Q; Liang L; Li B
Breast Cancer; 2020 Jul; 27(4):573-585. PubMed ID: 31960363
[TBL] [Abstract][Full Text] [Related]
8. Adenosine-to-inosine Alu RNA editing controls the stability of the pro-inflammatory long noncoding RNA NEAT1 in atherosclerotic cardiovascular disease.
Vlachogiannis NI; Sachse M; Georgiopoulos G; Zormpas E; Bampatsias D; Delialis D; Bonini F; Galyfos G; Sigala F; Stamatelopoulos K; Gatsiou A; Stellos K
J Mol Cell Cardiol; 2021 Nov; 160():111-120. PubMed ID: 34302813
[TBL] [Abstract][Full Text] [Related]
9. Enhanced AZIN1 RNA editing and overexpression of its regulatory enzyme ADAR1 are important prognostic biomarkers in gastric cancer.
Okugawa Y; Toiyama Y; Shigeyasu K; Yamamoto A; Shigemori T; Yin C; Ichikawa T; Yasuda H; Fujikawa H; Yoshiyama S; Hiro J; Ohi M; Araki T; Kusunoki M; Goel A
J Transl Med; 2018 Dec; 16(1):366. PubMed ID: 30563560
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of ADAR1 into the cytoplasm correlates with a better prognosis of patients with oral squamous cells carcinoma.
Caponio VCA; Troiano G; Botti G; Pedicillo MC; Lo Russo L; Mastrangelo F; Ciavarella D; Losito NS; Aquino G; Nocini R; Santoro R; Santoro A; Lo Muzio L; Pannone G
J Oral Pathol Med; 2019 Feb; 48(2):108-114. PubMed ID: 30489667
[TBL] [Abstract][Full Text] [Related]
11. Combinatory RNA-Sequencing Analyses Reveal a Dual Mode of Gene Regulation by ADAR1 in Gastric Cancer.
Cho CJ; Jung J; Jiang L; Lee EJ; Kim DS; Kim BS; Kim HS; Jung HY; Song HJ; Hwang SW; Park Y; Jung MK; Pack CG; Myung SJ; Chang S
Dig Dis Sci; 2018 Jul; 63(7):1835-1850. PubMed ID: 29691780
[TBL] [Abstract][Full Text] [Related]
12. A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer.
Nakano M; Fukami T; Gotoh S; Nakajima M
J Biol Chem; 2017 Mar; 292(12):4873-4884. PubMed ID: 28188287
[TBL] [Abstract][Full Text] [Related]
13. ADAR1 promotes the epithelial-to-mesenchymal transition and stem-like cell phenotype of oral cancer by facilitating oncogenic microRNA maturation.
Liu X; Fu Y; Huang J; Wu M; Zhang Z; Xu R; Zhang P; Zhao S; Liu L; Jiang H
J Exp Clin Cancer Res; 2019 Jul; 38(1):315. PubMed ID: 31315644
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer.
Kung CP; Cottrell KA; Ryu S; Bramel ER; Kladney RD; Bao EA; Freeman EC; Sabloak T; Maggi L; Weber JD
Oncogene; 2021 Jan; 40(1):189-202. PubMed ID: 33110236
[TBL] [Abstract][Full Text] [Related]
15. A panel of 8-lncRNA predicts prognosis of breast cancer patients and migration of breast cancer cells.
Zhu L; Cui K; Weng L; Yu P; Du Y; Zhang T; Liu H; Li B; Ma W
PLoS One; 2021; 16(6):e0249174. PubMed ID: 34086679
[TBL] [Abstract][Full Text] [Related]
16. Increase in ADAR1p110 activates the canonical Wnt signaling pathway associated with aggressive phenotype in triple negative breast cancer cells.
Morales F; Pérez P; Tapia JC; Lobos-González L; Herranz JM; Guevara F; de Santiago PR; Palacios E; Andaur R; Sagredo EA; Marcelain K; Armisén R
Gene; 2022 Apr; 819():146246. PubMed ID: 35122924
[TBL] [Abstract][Full Text] [Related]
17. Activation of AZIN1 RNA editing is a novel mechanism that promotes invasive potential of cancer-associated fibroblasts in colorectal cancer.
Takeda S; Shigeyasu K; Okugawa Y; Yoshida K; Mori Y; Yano S; Noma K; Umeda Y; Kondo Y; Kishimoto H; Teraishi F; Nagasaka T; Tazawa H; Kagawa S; Fujiwara T; Goel A
Cancer Lett; 2019 Mar; 444():127-135. PubMed ID: 30583079
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive lncRNA LINC00624 promotes tumor progression and therapy resistance through ADAR1 stabilization.
Zhang Q; Xiu B; Zhang L; Chen M; Chi W; Li L; Guo R; Xue J; Yang B; Huang X; Shao ZM; Huang S; Chi Y; Wu J
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252997
[TBL] [Abstract][Full Text] [Related]
19. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer.
Fan CN; Ma L; Liu N
J Transl Med; 2018 Sep; 16(1):264. PubMed ID: 30261893
[TBL] [Abstract][Full Text] [Related]
20. ADAR1 and AZIN1 RNA editing function as an oncogene and contributes to immortalization in endometrial cancer.
Nakamura K; Shigeyasu K; Okamoto K; Matsuoka H; Masuyama H
Gynecol Oncol; 2022 Aug; 166(2):326-333. PubMed ID: 35697535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
